Penting, 5 Suplemen yang Ampuh Meningkatkan Imun Tubuh bisnis.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bisnis.com Daily Mail and Mail on Sunday newspapers.
Daiichi Sankyo Company, Limited: DESTINY-CRC02 Phase 2 Trial of ENHERTU Initiated in Patients with HER2 Overexpressing Advanced Colorectal Cancer
Interstitial Lung Disease Pneumonitis
Severe, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, can occur in patients treated with ENHERTU. Advise patients to immediately report cough, dyspnea, fever, and/or any new or worsening respiratory symptoms. Monitor patients for signs and symptoms of ILD. Promptly investigate evidence of ILD. Evaluate patients with suspected ILD by radiographic imaging. Consider consultation with a pulmonologist. For asymptomatic ILD/pneumonitis (Grade 1), interrupt ENHERTU until resolved to Grade 0, then if resolved in =28 days from date of onset, maintain dose. If resolved in >28 days from date of onset, reduce dose one level. Consider corticosteroid treatment as soon as ILD/pneumonitis is suspected (e.g., =0.5 mg/kg/day prednisolone or equivalent). For symptomatic ILD/pneumonit
Using iodine as catalyst to advance the sustainability of pharmaceutical syntheses
Synthesizing pharmaceuticals for cancer, viral diseases, and other medical conditions is slow work. A particularly challenging chemical transformation is to start with what s known as an unactivated alkene a common molecular building block and end up with a vicinal diamine; i.e., installation of two nitrogen units into carbon carbon double bonds. The result is a chemical unit that s present in medications for influenza and colorectal cancer.
Commonly, researchers must use rare, toxic metals and harsh reaction conditions to complete this transformation. Using a more sustainable catalyst for the reaction could solve such problems. Previous research has attempted to do so, yet with only limited success.
Study could lead to the development of novel treatments for drug-resistant cancers
ETC-159, a made-in-Singapore anti-cancer drug that is currently in early phase clinical trials for use in a subset of colorectal and gynecological cancers, could also prevent some tumors from resisting therapies by blocking a key DNA repair mechanism, researchers from Duke-NUS Medical School and the Agency for Science, Technology and Research (A STAR) in Singapore reported in the journal
EMBO Molecular Medicine.
Among the many therapies used to treat cancers, inhibitors of the enzyme poly (ADP ribose) polymerase (PARP) prevent cancer cells from repairing naturally occurring DNA damage, including unwanted/harmful breaks in the DNA. When too many breaks accumulate, the cell dies.
Could the next health care crisis to hit our country be more people battling late-stage cancer? The pandemic has delayed cancer screenings and detection, which can have a major impact on outcomes.